Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stephen Tudhope is active.

Publication


Featured researches published by Stephen Tudhope.


European Journal of Pharmacology | 1993

Characterisation of the peptido-leukotriene receptor PL2 on the ferret spleen strip.

Phillip J. Gardiner; Peter Norman; Nigel J. Cuthbert; Stephen Tudhope; Trevor S. Abram

The peptido-leukotriene receptor(s) (PL) on the ferret isolated spleen strip have been characterised by functional studies using the naturally occurring leukotrienes (LTs), a range of structurally distinct PL antagonists, and by ligand binding studies. LTB4 (0.01-10 microM) was inactive on ferret spleen whereas LTC4, LTD4 and LTE4 produced concentration-related contractions with maximal responses, relative to noradrenaline, of 57% (EC50 0.28 microM), 60% (EC50 0.5 microM) and 7% respectively. The leukotriene responses were unaltered by L-serine borate, L-cysteine, indomethacin, phentolamine, propranolol, mepyramine, methysergide or atropine, suggesting that the peptido-leukotrienes were acting through distinct PL receptors. The PL1 antagonists, FPL 55712 (0.01-10 microM), ICI 198615 (10 microM), SK&F 104353 (10 microM) and MK541 (10 microM) were all inactive against LTC4- or LTD4-induced contractile responses. LTE4 was a partial agonist with respect to LTC4 and LTD4 with pKB values of 5.8 and 5.5 respectively. Nifedipine (0.1 microM) produced a rightward shift of the concentration-response curves to both LTC4 and LTD4 and depressed their maximal responses. An unacceptably high level of non-specific binding of [3H]LTD4 to membrane preparations of ferret spleen prevented characterisation of this receptor by ligand binding. These results suggest that the ferret spleen has a homogeneous population of a PL receptor type which is insensitive to existing PL1 receptor antagonists. The functional characteristics of this PL receptor type are similar to those of the PL2 receptor on other tissues. The absence of PL1 receptors on this tissue makes it particularly useful in identifying new and selective drug tools for the PL2 receptor.


Bioorganic & Medicinal Chemistry Letters | 1993

A new structural analogue antagonist of peptido-leukotrienes. The discovery of bay x7195

Trevor S. Abram; H. Böshagen; J.E. Butler; Nigel J. Cuthbert; Hilary P Dr Francis; Phillip J. Gardiner; W. Hartwig; H.C. Kluender; Peter Norman; Heinrich Meier; Ulrich Rosentreter; K.H. Schlemmer; Stephen Tudhope; W.A. Taylor

Abstract Systematic modification of LTD4 has led to the discovery of BAY x7195, a potent, selective, orally-active peptido-leukotriene antagonist.


European Journal of Pharmacology | 1994

Characterisation of leukotriene receptors on rat lung strip

Peter Norman; Trevor S. Abram; Nigel J. Cuthbert; Stephen Tudhope; Phillip J. Gardiner

The leukotriene receptor(s) present on rat lung strip have been characterised using the natural agonists, a selective mimetic, and potent (cysLT1) selective leukotriene receptor antagonists. Leukotriene C4 and leukotriene D4 displayed comparable contractile potencies whilst leukotriene E4 was less potent. However, both leukotriene D4 and leukotriene E4 were found to be partial agonists relative to leukotriene C4. Responses to all three leukotrienes were competitively antagonised by ICI 198615 (1-((2-methoxy-(4-phenylsulfonyl)-aminocarbonyl)-phenyl) methyl)-1H-indazol-6-yl) carbonic acid cyclopentyl ester), SK&F 104353 (2-(R)-hydroxy-3(S)-(2-carboxyethylthio)-3-(2-[8-phenyloctyl ]- phenyl)propanoic acid, and MK571 (+/-(E)-3-[3-[2-(7-chloro-2-quinolin-yl)ethenyl]-phenyl)- ([3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]thio]propanoic acid) with comparable affinities irrespective of the agonist used. This indicates that rat lung contains a homogeneous population of leukotriene receptors and that they are of the CysLT1 type.


European Journal of Pharmacology | 1994

BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes

Stephen Tudhope; Nigel J. Cuthbert; Trevor S. Abram; Michael A. Jennings; Robert J. Maxey; Angela M. Thompson; Peter Norman; Phillip J. Gardiner


Archive | 1996

2-amino-heterocycles and therapeutic uses therefor

Mazen Es-Sayed; Masaru Yamamoto; Klaus Frobel; Chris Poll; Suzanna Grix; Stephen Tudhope


Archive | 1989

Alkenoic acid derivatives

Ulrich Rosentreter; Harold Kluender; Trevor S. Abram; Peter Norman; Stephen Tudhope


Archive | 1996

Leukotriene antagonistic benzoic acid derivatives

Trevor S. Abram; Nigel J. Cuthbert; Hilary P Dr Francis; Phillip J. Gardiner; Peter Norman; Stephen Tudhope


Annals of the New York Academy of Sciences | 1991

BAY u9773—an LTC4 Antagonist in the Guinea Pig Trachea

Nigel J. Cuthbert; Stephen Tudhope; Phillip J. Gardiner; Trevor S. Abram; Peter Norman; Angela M. Thompson; R. J. Maxey; Michael A. Jennings


Archive | 1996

Use of hetarylacetic acid derivatives as leukotriene inhibitors

Mazen Es-Sayed; Masaru Yamamoto; Klaus Frobel; Chris Poll; Suzanna Grix; Stephen Tudhope


Archive | 1996

Carbamic acid derivatives as leukotriene antagonists

Mazen Es-Sayed; Masaru Yamamoto; Klaus Frobel; Chris Poll; Suzanna Grix; Stephen Tudhope

Collaboration


Dive into the Stephen Tudhope's collaboration.

Researchain Logo
Decentralizing Knowledge